+86-0635-6175299

Company Details

Shandong Haohong Biotechnology Co., Ltd.

[Shandong,China]

Business Type:Manufacturer

Main Markets: Americas , Asia , East Europe , Europe , Middle East , North Europe , West Europe , Worldwide

Exporter:71% - 80%

Certs:Test Report, ISO9001
Language

Shandong Haohong Biotechnology Co., Ltd.

 HomeNewsSupply of high-quality Apixaban API and Intermediates

Supply of high-quality Apixaban API and Intermediates

2021-09-10

What is Apixaban?

Apixaban (inn, trade name eliquis) is an anticoagulant used to prevent venous thromboembolism and atrial fibrillation stroke. It is a direct factor Xa inhibitor. Apixaban has been listed in Europe since May 2011. The drug was developed by a joint venture between Pfizer and Bristol Myers Squibb. It is used to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip or knee arthroplasty.

Shandong Haohong Biotechnology Co., Ltd is mainly focuses on the development of anti-cancer, anti-diabets series of API and its advanced intermediates. The main products include Bicalutamide, enzalutamide, apalutamide, macitentan, cabozantinib, ceritinib, empagliflozin, Rivaroxaban, and Apixaban,etc. In line with the concept of "truth-seeking, innovation and integrity", we had exported our products to the United States, European countries, Japan, India, Bangladesh and other overseas markets. At present, Our company has dozens of advanced intermediates, all of which are commercialized.

Apixaban API and Intermediates has always been one of the main products promoted by our company.The product purity is at least 99%.We can offer best quality product with perfect service, full documents support, factory audit is availbale.

Our Apixaban API and Intermediates list is as following, we have all the below intermedites offering all year.

Apixaban 2

If you want to know more information about our company and products, please visit our website at http://www.haohongpharma.com. We will offer the best price and the best quality for you.

Previous: FDA Breakthrough Designation Granted to CytoSorbents' DrugSorb-ATR for Removal of Apixaban and Rivaroxaban to Reduce the Risk of Serious Bleeding in Urgent Cardiothoracic Surgery

Next: Supply of high-quality Rivaroxaban API and Intermediates

 HomeNewsSupply of high-quality Apixaban API and Intermediates

Shandong Haohong Biotechnology Co., Ltd.